The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile

Alana Aragón-Herrera, Manuel Otero-Santiago, Laura Anido-Varela, Sandra Moraña-Fernández, Manuel Campos-Toimil, Tomás García-Caballero, Luis Barral, Estefanía Tarazón, Esther Roselló-Lletí, Manuel Portolés, Oreste Gualillo, Isabel Moscoso, Ricardo Lage, José Ramón González-Juanatey, Sandra Feijóo-Bandín, Francisca Lago

Open source

DOI: 10.3389/fphar.2022.827033
Published: 2022-02-02
Container: Frontiers in Pharmacology
Publisher: Frontiers Media SA
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fphar.2022.827033,
  title = {The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile},
  author = {Alana Aragón-Herrera and Manuel Otero-Santiago and Laura Anido-Varela and Sandra Moraña-Fernández and Manuel Campos-Toimil and Tomás García-Caballero and Luis Barral and Estefanía Tarazón and Esther Roselló-Lletí and Manuel Portolés and Oreste Gualillo and Isabel Moscoso and Ricardo Lage and José Ramón González-Juanatey and Sandra Feijóo-Bandín and Francisca Lago},
  year = {2022},
  journal = {Frontiers in Pharmacology},
  doi = {10.3389/fphar.2022.827033},
  url = {https://doi.org/10.3389/fphar.2022.827033}
}

RIS

TY  - JOUR
TI  - The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile
AU  - Alana Aragón-Herrera
AU  - Manuel Otero-Santiago
AU  - Laura Anido-Varela
AU  - Sandra Moraña-Fernández
AU  - Manuel Campos-Toimil
AU  - Tomás García-Caballero
AU  - Luis Barral
AU  - Estefanía Tarazón
AU  - Esther Roselló-Lletí
AU  - Manuel Portolés
AU  - Oreste Gualillo
AU  - Isabel Moscoso
AU  - Ricardo Lage
AU  - José Ramón González-Juanatey
AU  - Sandra Feijóo-Bandín
AU  - Francisca Lago
PY  - 2022
JO  - Frontiers in Pharmacology
DO  - 10.3389/fphar.2022.827033
UR  - https://doi.org/10.3389/fphar.2022.827033
ER  -

APA

Aragón-Herrera, A., Otero-Santiago, M., Anido-Varela, L., Moraña-Fernández, S., Campos-Toimil, M., García-Caballero, T., Barral, L., Tarazón, E., Roselló-Lletí, E., Portolés, M., Gualillo, O., Moscoso, I., Lage, R., González-Juanatey, J. R., Feijóo-Bandín, S., & Lago, F. (2022). The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2022.827033

Source records

crossref · retrieved 2026-09-27T12:24:46.890Z